Heart failure (HF) is a heterogeneous disease resulting from a number of common pathological stimuli including, but not limited to, long-standing hypertension, profound inflammation, and overactivation of neurohumoral pathways [@bib1]. HF is a major public health problem in the United States, with a prevalence of 7 million people, and it is projected to affect more than 9 million people by 2030 [@bib2]. Due to its heterogeneous nature, the consequences of HF are not limited to cardiac pathology. Noncardiac comorbidities such as renal dysfunction and vascular dysfunction frequently accompany HF and further decrease patients' quality of life and clinical outcomes [@bib3], [@bib4]. For example, HF patients with renal dysfunction have greater chance for readmission, longer hospital stay, and worse prognosis, and vascular injury has been linked to reduced exercise capacity, leading to decreased quality of life [@bib5], [@bib6].

Neurohumoral dysregulation is a hallmark feature in many cardiovascular diseases including heart failure [@bib7], [@bib8], [@bib9], [@bib10]. Specifically, overactivation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) exacerbates HF symptoms and contributes to the development of comorbidities [@bib4], [@bib11], [@bib12]. In fact, efficacious first-line medications for HF such as beta-blockers, mineralocorticoid receptor antagonists, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) target the sympathetic nervous system (SNS) and the RAAS overactivity. However, these medications are imperfect and have several limitations. For example, beta-blockers, mineralocorticoid receptor antagonists, and ARBs are receptor antagonists designed to compete with endogenous ligands without altering or decreasing the levels of endogenous ligands, which potentially limits their vascular protective effects [@bib13], [@bib14]. Distinct from receptor antagonists, ACE inhibitors reduce the endogenous production of angiotensin II (Ang II), but its use is contraindicated in patients with certain cardiorenal syndromes due to unwanted side effects [@bib15]. Current treatments inadequately manage the diverse population of HF patients in a manner that effectively extends longevity and quality of life. Therefore, examination of novel pharmacotherapies that have the ability to protect multiple organ systems in heart failure is warranted.

H~2~S plays a key role in cardiovascular homeostasis and cardioprotection [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]. H~2~S wields a wide range of biological functions in the cardiovascular system, including mitochondria biogenesis, metabolic modulation, angiogenesis, vasodilation and blood pressure regulation, inhibition of inflammation, antioxidant, and antiapoptosis [@bib21]. Furthermore, H~2~S reportedly exerts protective effects in multiple organ systems including vasculature and the kidney [@bib22], [@bib23], [@bib24], both of which are involved in the pathogenesis and progression of HF. Taken together, H~2~S represents a promising therapeutic target for the treatment of HF and its comorbidities.

JK-1 is a novel, phosphorothioate-based synthetic H~2~S donor that releases H~2~S upon hydrolysis. Recently we reported that administration of JK-1 at the time of reperfusion significantly reduced infarct size and circulating troponin-I levels in a murine model of myocardial ischemia-reperfusion injury [@bib20]. In the present study, using a well-established pressure overload HF model, the efficacy of delayed therapy with JK-1 on cardiac, renal, and vascular injury and dysfunction in the setting of HF was investigated.

Methods {#sec1}
=======

Experimental compounds {#sec1.1}
----------------------

JK-1 and its control compound were designed and synthesized by Dr. Ming Xian et al. [@bib20]. The optimal dose of JK-1 was selected based on the results of a previous study investigating the infarct-sparing effects of JK-1 [@bib20]. The structures of JK-1 and control are described in [Figure 1A](#fig1){ref-type="fig"}.Figure 1Experimental Compounds and Experimental Protocol**(A)** Chemical structures of JK-1 and control. Hydrolysis of JK-1 yields H~2~S and the chemical backbone of JK-1, which was selected as Control. The control compound is devoid of sulfur and does not release H~2~S. **(B)** Experimental design and protocol. At 1 week following baseline echocardiography, mice were subjected to TAC or sham TAC surgery. Mice were studied for a period of 18 weeks following TAC. The H~2~S donor, JK, was administered at either 3 or 10 weeks following TAC at a dose of 100 μg/kg b.i.d. through i.p. injection. This study involved 4 groups: sham TAC, HF plus Control compound, HF plus JK-1 administered at 3 weeks following TAC, or HF plus JK-1 administered starting at 10 weeks post TAC. b.i.d. = twice daily; BNP = B-type natriuretic peptide; HF = heart failure; LV = left ventricle; RAAS = renin-angiotensin-aldosterone system; TAC = transverse aortic constriction.

Experimental animals {#sec1.2}
--------------------

Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine) were 9 weeks of age at the time of study initiation. All experimental protocols were approved by the Institute for Animal Care and Use Committee at LSU Health Sciences Center and conformed to the Guide for the Care and Use of Laboratory Animals. All experimental animals received humane care in accordance with National Society of Medical Research and National Institutes of Health tenets.

Transverse aortic constriction protocol {#sec1.3}
---------------------------------------

Cardiac hypertrophy and heart failure were induced through transverse aortic constriction (TAC) as previously described [@bib19], [@bib25], [@bib26].

Experimental design and treatment regimen {#sec1.4}
-----------------------------------------

Sham or TAC procedures were performed 1 week after baseline echocardiography. All mice subjected to the TAC procedure were randomly assigned to 1 of 3 study groups. One group received control treatment starting at 3 weeks post TAC and continued until 18 weeks post TAC. The second group was treated with JK-1 starting at 3 weeks post TAC. The third group started with control at 3 weeks post TAC and were then switched to JK-1 at 10 weeks post TAC. All treatments were administered twice a day at a dosage of 100 μg/kg (200 μg/kg/day) through i.p. injection. A detailed experimental protocol is shown in [Figure 1B](#fig1){ref-type="fig"}.

Echocardiography {#sec1.5}
----------------

Echocardiography was performed at baseline and once every 3 weeks (model Vevo-2100 ultrasonography system; Visual Sonic, Baltimore, Maryland) as previously described [@bib25]. M-mode long-axis views were used to measure the thickness of interventricular septal walls at systole and diastole and left ventricle (LV) posterior wall at systole and diastole. LV chamber diameters at end systole and end diastole and LV ejection fraction (LVEF) were also measured using M-mode long-axis images.

LV hemodynamics assessment {#sec1.6}
--------------------------

Invasive hemodynamic measurement was performed at the 18-week endpoint using a 1.2-F transonic pressure catheter. The pressure catheter was inserted into the right common carotid and advanced into the LV. Systolic and diastolic arterial blood pressure, LV end diastolic pressure, and relaxation constant Tau values were recorded. Equally elevated systolic blood pressure across groups indicates a successful TAC procedure ([Supplemental Figure S3A](#appsec1){ref-type="sec"}).

Histological assessment {#sec1.7}
-----------------------

Cardiac and renal fibrosis were assessed at the 18-week endpoint as previously described [@bib26]. To quantify global fibrosis from the Picrosirius red-stained slides, fluorescent images were obtained (original magnification ×20) using an Olympus (model BX53-DP80, Tokyo, Japan) system and analyzed using ImageJ software (U.S. National Institutes of Health, Bethesda, Maryland).

Quantitative PCR {#sec1.8}
----------------

RNA was isolated from the heart and kidney tissues of control and JK-1-treated mice at 18 weeks post TAC. One milligram of RNA was transcribed using I-script cDNA synthesis kit (Bio-Rad, Portland, Maine). TaqMan primers for collagen 1a1 (Col1a1), collagen 3a1 (Col3a1), interleukin (IL)-6, connective tissue growth factor (CTGF), and fibronectin (FN1) were used to amplify by quantitative polymerase chain reaction (qPCR). For real-time qPCR experiments, 18S ribosomal RNA was used as a housekeeping gene, and 2^-delta-deltaCT^ values corrected to 18S rRNA were used for data analysis.

Circulating B-type natriuretic peptide quantification {#sec1.9}
-----------------------------------------------------

Circulating B-type natriuretic peptide (BNP) levels were measured at 18 weeks post TAC using an enzyme immunoassay (catalog number EK-011-23; Phoenix Pharmaceuticals, Burlingame, California).

Plasma creatinine quantification {#sec1.10}
--------------------------------

Creatinine levels were measured at 18 weeks post TAC using a commercially available assay kit (catalog number ab65340, Abcam, Cambridge, Massachusetts).

Aortic vascular reactivity assessment {#sec1.11}
-------------------------------------

Vascular function was measured in isolated segments (3 mm in length) of thoracic aorta as previously described [@bib27] at 18 weeks following TAC in all study groups. Vascular rings were equilibrated for 60 min and then pre-contracted with phenylephrine (1 μM). The vascular rings were then challenged with increasing concentrations of acetylcholine (10^−9^ to 10^−5)^ and sodium nitroprusside (SNP) at concentrations from 10^−10.5^ to 10^−6.5^. Data are reported as percent of relaxation from maximum contraction to phenylephrine.

Exercise capacity assessment {#sec1.12}
----------------------------

Treadmill exercise capacity was measured using an rodent treadmill (IITC, Woodland Hills, California) at 18 weeks post TAC as previously described with modifications [@bib28]. Briefly, immediately before the test, mice were put on the treadmill to acclimate for 15 min. Then, the mice are subjected to a slow walk/run period to be familiarized with treadmill running. In this period, the treadmill is set to start at 0 m/min speed and increased by 1 m/min every min for 10 min. Finally, in the test phase, the treadmill was set to a 30° incline, and the starting speed was set to 10 m/min and programed to increase by 2.67 m/min every min for 3 min, at which time the treadmill reached and maintained its top speed at 18 m/s. All mice were run at this setting until they reach a state of exhaustion. Duration and distance of the running and shocks per minute were recorded. Shocks per minute is a measurement of endurance. As mice felt tired and fell behind the speed of the treadmill, they received an electrical shock by the shocking grid. Higher shocks per min indicated lower endurance. A mouse was deemed to be exhausted when it spent more than 5 consecutive s at the back of the treadmill despite receiving electrical shocks repeatedly.

Circulating 8-isoprostane measurement {#sec1.13}
-------------------------------------

Plasma, myocardial, and renal 8-isoprostane levels were measured at 18 weeks post TAC by using an enzyme- linked immunosorbent assay kit (catalog number 516351, Cayman Chemical, Ann Arbor, Michigan). Tissue levels of 8-isoprostane were adjusted based on protein concentration (catalog number 23225; Thermo Fisher Scientific, Halethorpe, Maryland).

SNS and RAAS overactivation assessment {#sec1.14}
--------------------------------------

Renal norepinephrine levels were measured at 18 weeks post TAC, using an enzyme-linked immunosorbent assay kit (catalog number KA3836, Abnova, Taipei, Taiwan). Renin (catalog number EMREN1, Thermo Fisher Scientific), Ang II (catalog number ADI-900-204, Enzo Clinical Labs, Farmingdale, New York), and aldosterone (catalog number ADI-900-173, Enzo) levels were measured at 18 weeks post TAC using commercially available enzyme immunoassays. Renal levels of norepinephrine and aldosterone were adjusted based on protein concentration.

H~2~S and NO measurements {#sec1.15}
-------------------------

Plasma, myocardial, and renal H~2~S and nitric oxide (NO) levels were measured at 18 weeks post TAC as previously described [@bib18], [@bib29], [@bib30]. Tissue levels of H~2~S and NO were adjusted based on protein concentration.

cGMP measurement {#sec1.16}
----------------

Cardiac and renal cyclic guanosine monophosphate (cGMP) levels were measured at 18 weeks post TAC as previously described [@bib31].

Statistical analysis {#sec1.17}
--------------------

All data in this study are mean ± SEM. Differences in data among the groups were compared using 1-way ANOVA analysis or 2-way ANOVA analysis, using Prism 6 software (GraphPad, San Diego, California) followed by a Bonferroni multiple comparison test. A p value of \<0.05 was considered statistically significant. Presented data may have different numbers of animals per endpoint due to procedural complications, limited sample collection (i.e., plasma volume), or lack of participation in involuntary treadmill running. Prior to conducting statistical analysis, an outlier test was performed using "ROUT" method developed by Prism 6 to identify and remove any outlier in the data set.

Results {#sec2}
=======

Delayed treatment with JK-1 attenuates cardiac dilation, preserves LV ejection fraction, improves LV hemodynamics, and reduces cardiac fibrosis after TAC {#sec2.1}
---------------------------------------------------------------------------------------------------------------------------------------------------------

The effects of delayed therapy with JK-1 on the failing heart were evaluated using a TAC model of HF ([Figure 1](#fig1){ref-type="fig"}). Administration of JK-1 was initiated at 3 or 10 weeks post TAC and continued until 18 weeks post TAC. Mice treated with JK-1 initiated at 3 weeks or 10 weeks post TAC displayed significant reductions in LV chamber dimensions at end-diastole and end-systole compared to control mice ([Figures 2A and 2B](#fig2){ref-type="fig"}). In contrast, only the mice from 3-week post-TAC-treated group had preserved LVEF ([Figure 2C](#fig2){ref-type="fig"}), and there was no effect on LVEF in those that received JK-1 starting at 10 weeks following TAC. Invasive hemodynamic measurements revealed that delayed JK-1 treatment significantly decreased LV end-diastolic pressure and shortened relaxation constant Tau ([Figures 2D and 2E](#fig2){ref-type="fig"}). In addition, circulating BNP levels were significantly reduced in mice that received delayed JK-1 treatment ([Figure 2F](#fig2){ref-type="fig"}). Furthermore, the TAC-induced global LV hypertrophic response and subsequent wall thinning were attenuated in both of the JK-1 treatment groups ([Supplemental Figures S1A to S1D](#appsec1){ref-type="sec"}). We also demonstrated that, at the 18-week endpoint, the whole heart weight and left atrial weight-to-tibia length ratio were significantly lower in JK-1-treated mice than in control mice, indicating that JK-1 reduced pathological remodeling in pressure overload HF ([Supplemental Figures S2A to S2C](#appsec1){ref-type="sec"}).Figure 2LV Structure, Function, and Circulating BNP Levels at 18 Weeks Post TAC**(A) (B)** LVEDD and LVESD (mm) throughout the experimental protocol. **(C)** Percent of LVEF. **(D)** Left ventricular end-diastolic pressure (mm Hg) at 18 weeks following TAC. **(E)** LV relaxation constant Tau (ms) at 18 weeks post TAC. **(F)** Circulating BNP levels (ng/ml) in mice from Sham, HF + Control, HF + 3-week-delayed JK-1 treatment, and HF + 10-week-delayed JK-1 treatment. \*p \< 0.05 between Sham vs. HF + Control; \*\*p \< 0.01 between Sham vs. HF + Control; \*\*\*\*p \< 0.0001 between Sham vs. HF + Control; \#p \< 0.05 between HF + JK-1 3 weeks post TAC vs. HF + Control; \#\#\#p \< 0.001 between HF + JK-1 3 weeks post TAC vs. HF + Control; \#\#\#\#p \< 0.0001 between HF + JK-1 3 weeks post TAC vs. HF + Control; \$p \< 0.05 between HF + JK-1 10 weeks post TAC; \$\$\$p \< 0.001 between HF + JK-1 10 weeks post TAC; \$\$\$\$p \< 0.0001 between HF + JK-1 10weeks post TAC. LVEDD, LVESD, and LVEF data were analyzed with 2-way-ANOVA, whereas LVEDP, Tau, and circulating BNP data were analyzed with 1-way ANOVA. **Circles inside bars** denote sample size. LVEDD = left ventricular end-diastolic dimensions; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic dimensions; other abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Next, we evaluated the effects of delayed JK-1 treatment on cardiac fibrosis with PicroSirius red staining at 18 weeks post TAC. Representative photomicrographs of heart sections are shown in [Figure 3A](#fig3){ref-type="fig"}. Treatment with JK-1 initiated at 3 weeks post TAC significantly reduced cardiac fibrosis whereas there was no significant change when JK-1 treatment was initiated at 10 weeks post TAC ([Figure 3B](#fig3){ref-type="fig"}). Furthermore, 3-week-delayed JK-1 treatment mitigated the transcription of pro-fibrotic genes such as collagen 1a1, collagen 3a1, interleukin-6, connective tissue growth factor, and fibronectin in the heart ([Figure 3C](#fig3){ref-type="fig"}).Figure 3Cardiac Fibrosis at 18 Weeks Post TAC**(A)** Representative images (original magnification ×20) of Picrosirius red-stained cardiac tissue sections from HF + Control and HF + JK-1 (3 weeks and 10 weeks, respectively) delayed treatment. **(B)** Quantified cardiac fibrosis. **(C)** Relative fold changes in myocardial mRNA levels of a panel of fibrosis-related genes in mice from HF + Control, HF + JK-1 3 weeks post TAC, and HF + JK-1 10 weeks post TAC groups at 18 weeks post TAC. All data in [Figure 3](#fig3){ref-type="fig"} were analyzed with 1-way ANOVA. **Circles inside bars** denote sample size. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Delayed treatment with JK-1 ameliorates renal dysfunction and reduces renal fibrosis in HF {#sec2.2}
------------------------------------------------------------------------------------------

The effect of JK-1 on renal function in HF was assessed at 18 weeks post TAC by plasma creatinine measurements. Mice treated with Control exhibited impaired renal function as shown by elevated plasma creatinine levels that were compared to Sham mice. Mice treated with JK-1 initiated at 3 weeks post TAC and 10 weeks post TAC displayed significant reductions in plasma creatinine levels, indicating preserved renal function ([Figure 4D](#fig4){ref-type="fig"}). In addition, histological assessment of PicroSirius red-stained kidney sections revealed increased renal fibrosis in mice subjected to the TAC procedure and those that received Control treatment. Contrary to our observation in cardiac fibrosis, we saw significantly lessened amounts of renal fibrosis in mice that received 3-week-delayed or 10-week-delayed JK-1 treatment ([Figure 4A and 4B](#fig4){ref-type="fig"}). Furthermore, both 3-week- and 10-week-delayed JK-1 treatment significantly mitigated the transcription of interleukin-6 and connective tissue growth factor in the kidney, whereas only 3-week-delayed treatment significantly reduced the transcription of collagen 1a1 and fibronectin ([Figure 4C](#fig4){ref-type="fig"}).Figure 4Renal Fibrosis and Plasma Creatinine Levels at 18 Weeks Post TAC**(A)** Plasma creatinine levels. **(B)** Representative images (original magnification ×20) of Picrosirius red- stained renal tissue sections. **(C)** Quantified global renal fibrosis. **(D)** Relative fold changes in renal mRNA levels of fibrosis-related genes in mice from HF + Control, HF + JK-1 3 weeks post TAC, and HF + JK-1 10 weeks post TAC groups at 18 weeks post TAC. All data were analyzed with 1-way ANOVA. **Circles inside bars** denote the sample size. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Delayed treatment with JK-1 attenuates endothelial dysfunction in HF {#sec2.3}
--------------------------------------------------------------------

Vascular reactivity of isolated thoracic aortas to acetylcholine and SNP is shown in [Figure 5](#fig5){ref-type="fig"}. Aortas from mice that received the Control compound displayed significantly worsened responses to acetylcholine, as shown in concentration-response curve, maximal relaxation reached, and Half maximal effective concentration (EC~50~) values. Interestingly, delayed treatment with JK-1 (3 and 10 weeks delayed) resulted in better relaxation responses to acetylcholine ([Figures 5A to 5C](#fig5){ref-type="fig"}).Figure 5Aortic Vasorelaxation at 18 Weeks Post TACFreshly isolated thoracic aortic rings were allowed to equilibrate, and pre-contracted with 1 μM phenylephrine. **(A)** Concentration-response curve (% relaxation from 10^−9^ to 10^−5^). **(B)** EC~50~ (nM). **(C)** Maximal relaxation (%) achieved for acetylcholine (Ach)-mediated vasorelaxation in mice from Sham, HF + Control, HF + JK-1 3 weeks post TAC, and HF + JK-1 10 weeks post TAC groups at 18 weeks post TAC. **(D)** Concentration-response curve (% relaxation from 10^−10.5^ to 10^−6.5^) **(E)** EC50 (nM), and **(F)** maximal relaxation (%) achieved for SNP mediated vasorelaxation in mice from Sham, HF + Control, HF + JK-1 3 weeks post TAC, and HF + JK-1 10 weeks post TAC groups at 18 weeks post TAC. \*p \< 0.05 between Sham vs. HF + Control; \*\*\*\*p \< 0.0001 between Sham vs. HF + Control; \# p \< 0.05 between HF + JK-1 3 weeks post TAC vs. HF + Control; \#\#p \< 0.01 between HF + JK-1 3 weeks post TAC vs. HF + Control; \#\#\#\#p \< 0.0001 between HF + JK-1 3 weeks post TAC vs. HF + Control; \$\$\$p \< 0.001 between HF + JK-1 10weeks post TAC; \$\$\$\$p \< 0.0001 between HF + JK-1 10weeks post TAC. Concentration-response curve were generated using a model of nonlinear regression with variable slope followed by 2-way-ANOVA analysis. EC~50~ and maximal relaxation data were analyzed with 1-way ANOVA. **Circles inside bars** denote the sample size. EC~50~ = half maximal effective concentration; SNP = sodium nitroprusside; other abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

We also evaluated vascular relaxation responses of isolated thoracic aorta to SNP. Aortas from mice that received the Control compound displayed worsened vasodilation only at concentrations of 1 and 10 nM SNP, and no significant differences were observed in maximal relaxation and EC~50~ ([Figures 5D to 5F](#fig5){ref-type="fig"}). Taken together, these data suggest that TAC-induced HF resulted in severe endothelial dysfunction, and delayed treatment with JK-1 partially corrected this dysfunction.

Delayed treatment with JK-1 enhanced treadmill exercise performance {#sec2.4}
-------------------------------------------------------------------

Reduced exercise capacity is one of the hallmark symptoms of HF in patients. We examined the effects of delayed therapy with JK-1 on exercise capacity using a rodent treadmill at 18 weeks post TAC ([Figure 6](#fig6){ref-type="fig"}). Mice from the HF + Control group displayed greatly reduced time to exhaustion and distance of running and experienced higher numbers of shocks per min than Sham mice, suggesting that TAC-induced HF resulted in reduced exercise capacity and lower endurance. Mice that received JK-1 treatment initiated at 3 or 10 weeks post TAC showed significantly improved exercise capacity as they had better treadmill running duration and distance and received fewer shocks per min.Figure 6Treadmill Exercise Capacity at 18 Weeks Post TACExercise capacity was evaluated in all study groups at 18 weeks following TAC surgery. **(A)** Duration (min) of the running before exhaustion. **(B)** Distance (m) of the running before exhaustion. **(C)** Shocks per minute in mice from Sham, HF + Control, HF + JK-1 3 weeks post TAC, and HF + JK-1 10 weeks post TAC groups at 18 weeks post TAC. All data were analyzed with 1-way ANOVA. **Circles inside bars** denote the sample size. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Delayed treatment with JK-1 augments H~2~S and NO bioavailability, and reduced systemic and tissue levels of oxidative stress {#sec2.5}
-----------------------------------------------------------------------------------------------------------------------------

Next, we examined the effects of delayed JK-1 treatment on the bioavailability of H~2~S, NO, and levels of oxidative stress at 18 weeks post TAC ([Figure 7](#fig7){ref-type="fig"}). Mice treated with JK-1 starting at 3 or 10 weeks post TAC had significantly elevated levels of circulating H~2~S ([Figure 7A](#fig7){ref-type="fig"}), myocardial tissue H~2~S ([Figure 7B](#fig7){ref-type="fig"}), and renal tissue H~2~S ([Figure 7C](#fig7){ref-type="fig"}), further verifying the ability of JK-1 to donate pharmacologically relevant concentrations of H~2~S.Figure 7H~2~S and NO Bioavailability and 8-Isoprostane Levels at 18 Weeks Post TACH~2~S levels (μM) in plasma **(A)**, myocardial tissue **(B)**, and renal tissue **(C)**. Nitrite levels (μM) in plasma **(D)**, myocardial tissue **(E**), and renal tissue **(F)**. 8-Isoprostane (8-Iso) levels (pg/ml) in circulation **(G)**, myocardial tissue **(H)**, and renal tissue **(I)** in mice from Sham, HF + Control, HF + JK-1 3 weeks post TAC, and HF + JK-1 10 weeks post TAC groups at 18 weeks post TAC. All data were analyzed with 1-way ANOVA. **Circles inside bars** denote the sample size. Abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Multiple studies have previously reported that H~2~S augments the bioavailability and signaling of NO [@bib18], [@bib31], [@bib32], [@bib33]. The current study found that JK-1 treatment initiated at 3 or 10 weeks post TAC resulted in significantly elevated levels of nitrite in circulation, heart, and kidney ([Figures 7D to 7F](#fig7){ref-type="fig"}). In addition, significantly elevated levels of cGMP were also observed in cardiac and renal tissue at 18 weeks post TAC in mice receiving JK-1 treatment ([Supplemental Figures S4A and S4B](#appsec1){ref-type="sec"}).

In addition, it has been reported that both H~2~S and NO are powerful antioxidants [@bib31], [@bib34]. Therefore, we examined the levels of oxidative stress by using 8-isoprostane as a biomarker ([Figures 7G to 7I](#fig7){ref-type="fig"}). TAC-induced HF resulted in elevated oxidative stress as the mice receiving the Control compound exhibited significantly higher levels of 8-isoprostane in circulation, heart, and kidney. Such elevation in oxidative stress was ameliorated by both the 3- and 10-week-delayed JK-1 treatment.

Delayed treatment with JK-1 reduced renal norepinephrine contents, attenuated RAAS signaling in HF {#sec2.6}
--------------------------------------------------------------------------------------------------

Neurohumoral dysregulation is a significant contributor to the pathogenesis of HF and its co-morbidities [@bib14], [@bib35]. Specifically, overactivation of the SNS and the RAAS significantly exacerbates the severity of HF [@bib4]. In the current study, we evaluated the extent of SNS and RAAS overactivation by measuring renal or circulating levels of norepinephrine, renin, Ang II, and aldosterone ([Figure 8](#fig8){ref-type="fig"}). We observed that TAC-induced HF significantly activated the SNS as mice receiving the Control compound displayed nearly 20-fold increase in renal norepinephrine content. JK-1 treatment initiated at 3 or 10 weeks post TAC significantly attenuated renal norepinephrine content compared to mice receiving Control ([Figure 8A](#fig8){ref-type="fig"}). Furthermore, delayed JK-1 treatment ameliorated RAAS activation as mice that received 3-week- and 10-week-delayed JK-1 treatment had significantly reduced levels of circulating renin ([Figure 8B](#fig8){ref-type="fig"}), circulating Ang II ([Figure 8C](#fig8){ref-type="fig"}), and circulating aldosterone ([Figure 8D](#fig8){ref-type="fig"}) compared to those that received Control. Similarly, renal aldosterone content was significantly reduced in mice that received either 3-week- or 10-week-delayed JK-1 therapy ([Figure 8E](#fig8){ref-type="fig"}).Figure 8Renal Norepinephrine Content, Circulating Renin, Ang II, and Aldosterone Levels at 18 Weeks Post TAC**(A)** Renal tissue norepinephrine content (ng/ml). **(B)** Plasma renin (ng/ml). **(C)** Plasma Ang II (pg/ml). **(D)** Circulating Aldo levels (pg/ml). **(E)** Renal Aldo levels (pg/ml) in mice from Sham, HF + Control, HF + JK-1 3 weeks post TAC, and HF + JK-1 10 weeks post TAC groups at 18 weeks post TAC. All data were analyzed with 1-way ANOVA. **Circles inside bars** denote the sample size. Aldo = aldosterone; Ang II = angiotensin II; other abbreviations as in [Figure 1](#fig1){ref-type="fig"}.

Discussion {#sec3}
==========

It was previously shown that pharmacological H~2~S therapy ameliorates TAC-induced HF severity [@bib19], [@bib25], [@bib36], [@bib37]. However, one major limitation of those studies is that the experimental H~2~S therapies were administered prior to or right after the induction of HF by TAC. Such treatment regimens do not reflect clinical scenarios where medications are given to patients after the establishment of cardiac dysfunction or failure [@bib8], [@bib38]. The current study examined the efficacy of a novel H~2~S donor, JK-1, in TAC-induced HF with a delayed treatment approach. To better simulate the clinical situation, we initiated the H~2~S therapy with JK-1, either at 3 or 10 weeks post TAC. At 3 weeks post TAC, echocardiographic assessment revealed that all mice subjected to TAC started to develop cardiac hypertrophy. At 10 weeks following TAC, all mice that were subjected to TAC and received the Control compound had LVEFs below 45%.

We observed significant preservation of LVEF in mice treated with JK-1 starting at 3 weeks post TAC but not in those started at 10 weeks post TAC. This preservation in LVEF was accompanied by reduction in cardiac fibrosis, which was also seen only in mice starting to receive H~2~S therapy at 3 weeks post TAC. These data suggest that 10-week-delayed H~2~S therapy fails to reverse established cardiac fibrosis and pathological remodeling in the failing heart. Interestingly, despite its neutral effects in LVEF and cardiac fibrosis, 10-week-delayed JK-1 therapy ameliorated other aspects of cardiac dysfunction. We observed significantly attenuated LV chamber dilatation, lower LVEDP, and shorter relaxation constant Tau with both the 3-week- and the 10-week-delayed treatment compared to Control mice. These improvements in LV chamber size translated into significant reductions in circulating BNP levels for both the 3-week- and the 10-week-delayed JK-1 treatments. Taken together, these data demonstrate that delayed H~2~S therapy is efficacious in TAC-induced HF with greater improvements in LV function when treatment is initiated early.

HF is a systemic condition that deteriorates the function of multiple organ systems including the kidney and the vasculature [@bib3], [@bib4], [@bib5], [@bib6], [@bib15], [@bib39], [@bib40]. As chronic HF progresses, cardiac pathologies such as overactive SNS and RAAS, inflammation, and excessive oxidative stress induces renal injury and impairs normal renal function. Such phenomenon is defined as type II cardiorenal syndrome and often results in poorer prognosis and survival [@bib5], [@bib35]. To date, no pharmacological therapeutic has been developed to simultaneously target both the failing heart and the injured kidney. Previous studies have reported that H~2~S therapies effectively ameliorated renal dysfunction in several animal models of kidney diseases through differential mechanisms, suggesting that H~2~S-based therapies may be efficacious in treating both the heart and the kidney in HF [@bib14], [@bib38], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47]. In consistent with previous literature, we observed that the mice received Control developed type-II cardiorenal syndrome as evidenced by elevated levels of plasma creatinine and renal fibrosis at 18 weeks post TAC [@bib39]. Delayed treatment with JK-1 started at 3 or 10 weeks post TAC significantly lowered plasma creatinine levels, renal fibrosis, as well as the transcriptional levels of pro-fibrotic genes such as collagen 1a1, collagen 3a1, interleukin 6, connective tissue growth factor, and fibronectin. Taken together, our data provides the first evidence that H~2~S therapy is efficacious for the treatment of cardiorenal syndrome induced by TAC.

In addition to cardiorenal syndrome, endothelial injury and dysfunction is another commonly seen comorbidities in HF [@bib3], [@bib4]. Endothelium is a monolayer of cells covering the inner surface of blood vessels that mediates the vascular hemostasis through providing NO, antiproliferative and anti-inflammatory actions. Endothelial dysfunction results in the inactivation of endothelial NOS (eNOS) and attenuated NO bioavailability, over-produced inflammatory cytokines, and increased oxidative stress, which further exacerbate the progression of HF [@bib6], [@bib48], [@bib49]. Multiple studies have reported that H~2~S augments endothelial function via reducing oxidative stress, promoting eNOS activity, and other mechanisms [@bib16], [@bib33], [@bib50], [@bib51]; However, there is a lack of information regarding the endothelium-protective actions of H~2~S in the setting of HF. In the current study, we observed that the aortic rings of isolated from HF + Control mice exhibited diminished response to acetylcholine, verifying that TAC- induced HF indeed caused severe endothelium dysfunction. More importantly, delayed H~2~S treatment with JK-1 attenuated endothelium dysfunction as shown by improved concentration-response curve, achieving greater maximal relaxation, and resulting in lower EC50. This improvement in the vasodilatory response to acetylcholine was also reflected in enhanced NO bioavailability and signaling following JK-1 treatment.

Severe exercise intolerance is a primary chronic symptom associated with decreased quality of life in patients with HF, even when stable and well compensated [@bib52]. More recently, the endothelium has emerged as a therapeutic target for exercise intolerance in HF [@bib6], [@bib53]. Given the prominent endothelium-protective effects of JK-1 in HF, we measured the exercise capacity and we observed that TAC- induced HF significantly impaired the exercise capacity of mice treated with control, whereas JK-1 treatment initiated at 3 and 10 weeks post TAC significantly increased the duration and distance of treadmill running. Interestingly, despite the neutral effect on LVEF, the mice received 10-week-delayed JK-1 treatment displayed 3-fold increase in duration and distance of running. This suggests that vascular endothelial function plays an independent role from cardiac function in H~2~S-mediated improvement in exercise capacity in TAC- induced HF.

Additionally, we examined the effects of delayed JK-1 treatment on the levels of SNS and RAAS activation. In the pathogenesis of HF, maladaptive SNS signaling increases in response to decreased cardiac output, which in turn, activates RAAS [@bib8]. SNS and RAAS overactivation are major maladaptive neurohumoral alterations in HF that accelerate the exacerbation of HF and its comorbidities [@bib8], [@bib9]. Previously, it was reported that NO exerts sympathoinhibitory effects via attenuating the release of norepinephrine from neural terminals [@bib54]. More recently, it was discovered that elevation in oxidative stress in central nervous system resulted in systemic sympathoexcitation [@bib40]. Given the powerful antioxidant and NO-promoting effects of H~2~S, we propose that delayed therapy with JK-1 down regulates SNS and RAAS activation. We observed that renal norepinephrine content was significantly reduced in kidneys from mice received 3-week- and 10-week-delayed JK-1 treatment when compared to HF + Control. Reduction in renal norepinephrine content was accompanied by reduced levels of renin, Ang II, and aldosterone in the circulation.

Although we observed similar degree of reductions in plasma creatinine levels, renal fibrosis, renal norepinephrine content, renin, and aldosterone levels for both 3-week- and 10-week-delayed JK-1-treated groups, the 3-week-delayed treatment offered greater reductions in circulating Ang II, and greater increases in NO bioavailability and signaling. This resulted in greater improvements in cardiac and vascular function as well as exercise capacity. This observation suggests that although H~2~S therapy is efficacious in both early and late stages of the diseases, earlier intervention may offer better outcomes.

Study limitations {#sec3.1}
-----------------

We demonstrated the differential effects of 3-week-delayed versus 10-week-delayed JK-1 treatment in the context of pressure overload-induced heart failure; however, in order to verify the efficacy of JK-1 and fully understand its mechanism of action, further investigations using other heart failure models are warranted. In addition, although we showed that JK-1 treatment significantly reduced the plasma creatinine levels, a more clinically relevant index of kidney function would be glomerular filtration rate or urine creatinine-to-albumin ratio. Furthermore, the pharmacokinetics and effects of JK-1 treatment on naïve mice were not investigated in the current study. Such information would provide strong basis for the translation of JK-1 as a therapeutic agent.

Conclusions {#sec4}
===========

We have shown that delayed treatment with a novel and potent H~2~S donor, JK-1, protects multiple organs including the heart, peripheral arteries, and the kidneys against injury and dysfunctions in the setting of TAC- induced heart failure. Such protection in multiple organs translated into improved exercise capacity. Furthermore, our results demonstrate that delayed treatment with JK-1 reduced the overactivation of the SNS and RAAS, possibly through enhancing NO bioavailability and signaling, and reducing oxidative stress. We conclude that delayed H~2~S therapy is efficacious in HF, and is worthy of further development as a promising therapeutic for the treatment of HF and its comorbidities. Future studies will investigate the cellular and molecular mechanism by which H~2~S mitigates the overactivation of SNS and RAAS in HF.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** In the setting of heart failure, the lack of proper perfusion and the activation of maladaptive signaling pathways such as RAAS lead to renal and endothelial dysfunction. Similar to NO, H~2~S is a endogenous gaseous molecule that exerts protective effects on cardiovascular system. Here we used JK-1, a novel synthetic H~2~S donor, to simultaneously protect the heart, the kidneys, the vessels, and to improved exercise performance in mice subjected to heart failure.**TRANSLATIONAL OUTLOOK:** H~2~S-based therapeutics have been tested in heart failure patients and proven to be safe and bio-active. Our study identified that JK-1, a novel H~2~S donor, protects the heart against pressure overload-induced heart failure and reduces the collateral damages to the kidney and the endothelium. These findings support further clinical investigation of the efficacy of H~2~S-based therapies for treating heart failure and its comorbidities.
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